High-Dose rhBMP Increases Risk of Cancer

Share this content:
High-Dose rhBMP Linked to Increased Incidence of Cancer
High-Dose rhBMP Linked to Increased Incidence of Cancer

(HealthDay News) -- Patients receiving high-dose recombinant human bone morphogenetic protein-2 (rhBMP-2) as part of spine surgery have an increased risk of cancer and may be at risk for major complications, according to two studies published in the Sept. 4 issue of The Journal of Bone & Joint Surgery.

In an effort to examine the risk of new cancers in patients receiving high-dose rhBMP-2, Eugene J. Carragee, MD, from the Stanford University School of Medicine in Redwood City, Calif., and colleagues used data from a multicenter trial involving patients with degenerative lumbar spine conditions who underwent single-level instrumented posterolateral arthrodesis with high-dose rhBMP-2 in a compression-resistant matrix (rhBMP-2/CRM; 239 patients) or autogenous bone graft (control; 224 patients).

The researchers found that the incidence rate of new cancer events was 3.37 per 100 person-years in the rhBMP-2/CRM group versus 0.50 in the control group (incidence rate ratio, 6.75 at 2 years). At five years, the incidence of cancer events was still significantly greater in the rhBMP-2/CRM group.

Addisu Mesfin, M.D., from the University of Rochester in New York, and colleagues examined the short- and long-term outcomes and medical and surgical complications linked to high-dose rhBMP-2 in a cohort of 502 patients who received high-dose rhBMP-2 as part of spinal surgery.

The researchers found that the rates of intraoperative complications, perioperative major surgical complications, and perioperative major medical complications were 8.2%, 11.6%, and 11.6%, respectively. No significant association was found for rhBMP-2 with radiculopathy, seroma, or cancer.

"Major surgical complications occurred in 11.6% of patients, and 11.6% experienced major medical complications," Mesfin and colleagues write.

One or more authors from both studies, or their institutions, disclosed a financial tie with an entity in the biomedical arena.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs